Table 2

Baseline characteristics
All Diagnostic screening Care as usual
(n = 841) (n = 395) (n = 446)
Mean age in years ± sd 74.6 ± 6.3 75.4 ± 6.2 73.8 ± 6.3
Male sex, n (%) 418 (49.7%) 176 (44.6%) 242 (54.3%)
Complaints
MRC Dyspnoea score, median (IQR) 2 (2–3) 2 (2–3) 2 (2–3)
Reduced exercise tolerance questionnaire score, median (IQR) 2 (1–3) 2 (0–3) 2 (1–3)
Cardiovascular co-morbidities
Ischemic heart disease, n (%) 259 (30.8%) 127 (32.2%) 132 (29.6%)
Heart failure, n (%) 42 (5.0%) 22 (5.6%) 20 (4.5%)
Valvular disorders, n (%) 59 (7.0%) 24 (6.1%) 35 (7.8%)
Cardiac rhythm disorders, n (%) 116 (13.8%) 55 (13.9%) 61 (13.7%)
Hypertension, n (%) 591 (70.3%) 292 (73.9%) 299 (67.0%)
Hypercholesterolemia, n (%) 234 (27.8%) 94 (23.8%) 140 (31.4%)
Diabetes Mellitus, n (%) 262 (31.2%) 130 (32.9%) 132 (29.6%)
CVA or TIA, n (%) 99 (11.8%) 44 (11.1%) 55 (12.3%)
Non-cardiovascular co-morbidities
Visual impairment, n (%) 207 (24.6%) 98 (24.8%) 109 (24.4%)
Hearing impairment, n (%) 93 (11.1%) 43 (10.9%) 50 (11.2%)
COPD, n (%) 134 (15.9%) 68 (17.2%) 66 (14.8%)
Asthma, n (%) 78 (9.3%) 36 (9.1%) 42 (9.4%)
Mood disorders, n (%) 27 (3.2%) 11 (2.8%) 16 (3.6%)
Urinary tract problems, n (%) 90 (10.7%) 35 (8.9%) 55 (12.3%)
Osteoporosis, n (%) 58 (6.9%) 25 (6.3%) 33 (7.4%)
Malignancies, n (%) 51 (6.1%) 18 (4.6%) 33 (7.4%)
Anaemia, n (%) 14 (1.7%) 9 (2.3%) 5 (1.1%)
Renal insufficiency, n (%) 47 (5.6%) 12 (3.0%) 35 (7.8%)
Thyroid dysfunction, n (%) 63 (7.5%) 28 (7.1%) 35 (7.8%)
Osteoarthritis, n (%) 212 (25.2%) 126 (31.9%) 86 (19.3%)
Co-morbidities (number), median (IQR) 3 (3–4) 4 (3–4) 3 (3–5)
Drugs
Diuretics, n (%) 346 (41.1%) 169 (42.8%) 177 (39.7%)
ACE-i/ARBs, n (%) 478 (56.8%) 220 (55.7%) 258 (57.8%)
ß-blockers, n (%) 397 (47.2%) 185 (46.8%) 212 (47.5%)
Digitalis, n (%) 20 (2.4%) 12 (3.0%) 8 (1.8%)
Oral anticoagulants, n (%) 117 (13.9%) 49 (12.4%) 68 (15.2%)
Platelet antagonists, n (%) 402 (47.8%) 192 (48.6%) 210 (47.1%)
Treatment for hypercholesterolemia 488 (58.0%) 209 (52.9%) 279 (62.6%)
Anti-diabetic drugs, n (%) 223 (26.5%) 109 (27.6) 114 (25.6%)
Treatment for COPD or Asthma, n (%) 204 (24.3%) 91 (23.0%) 113 (25.3%)
Drugs (number), median (IQR) 6 (4–7) 5 (4–7) 6 (4–7)

baseline characteristics at selection based on electronic medical fileI Ischemic heart disease includes prior myocardial infarction, angina pectoris, coronary artery bypass grafting, and percutaneous coronary intervention; visual impairment includes cataract, blindness or glaucoma, ACE-i = angiotensin converting enzyme-inhibitor, ARBs = angiotensin receptor blockers.

van Mourik et al.

van Mourik et al. BMC Public Health 2012 12:385   doi:10.1186/1471-2458-12-385

Open Data